[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Dartnell J, Pilling J, Ferner R, Cane P, Lang-Lazdunski L: Malignant triton tumor of the brachial plexus invading the left thoracic inlet: a rare differential diagnosis of pancoast tumor. J Thorac Oncol; 2009 Jan;4(1):135-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant triton tumor of the brachial plexus invading the left thoracic inlet: a rare differential diagnosis of pancoast tumor.
  • Malignant triton tumor is a divergent malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation.
  • We report a case of malignant triton tumor arising in the brachial plexus of a 28-year-old women with neurofibromatosis type 1.
  • Fluorodeoxyglucose-positron emission tomography-computed tomography before excision demonstrated a tumor with a maximum standard uptake value of 21 at 4 hours postinjection.
  • The patient underwent complete excision of the tumor through median sternotomy and left supraclavicular approach.
  • Adjuvant radiotherapy and chemotherapy were planned but the patient died of metastatic disease within 3 months of surgical resection.
  • [MeSH-major] Brachial Plexus / pathology. Neurilemmoma / diagnosis. Pancoast Syndrome / diagnosis. Peripheral Nervous System Neoplasms / diagnosis. Thoracic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neurofibromatosis 1 / complications. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096322.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


2. Boujaoude J: Role of endoscopic ultrasound in diagnosis and therapy of pancreatic adenocarcinoma. World J Gastroenterol; 2007 Jul 21;13(27):3662-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of endoscopic ultrasound in diagnosis and therapy of pancreatic adenocarcinoma.
  • Since its advent more than 20 years ago, endoscopic ultrasound (EUS) has undergone evolution from an experimental to a diagnostic instrument and is now established as a therapeutic tool for endoscopists.
  • The curved linear array echoendoscope enables the visualization of a needle as it exits from the biopsy channel in the same plane of ultrasound imaging in real time.
  • This allows the endoscopist to perform a whole range of interventional applications ranging from fine needle aspiration (FNA) of lesions surrounding the gastrointestinal tract to celiac plexus block and drainage of pancreatic pseudocyst.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Endoscopy, Digestive System / methods. Endosonography / methods. Pancreatic Neoplasms / ultrasonography. Ultrasonography, Interventional / methods
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Autonomic Nerve Block / methods. Biopsy, Fine-Needle / methods. Catheter Ablation / methods. Celiac Plexus. Cholangiography / methods. Diagnosis, Differential. Drug Delivery Systems / methods. Humans. Neoplasm Staging / methods. Photochemotherapy / methods. Predictive Value of Tests. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659723.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  • [Other-IDs] NLM/ PMC4250635
  •  go-up   go-down


3. Ye C, Xi PC, Hu XG: Clinical analysis of uncinate process carcinoma of the pancreas. Hepatobiliary Pancreat Dis Int; 2003 Nov;2(4):605-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyse the clinical features of uncinate process carcinoma of the pancreas and the diagnosis and treatment of this malignancy.
  • Thirty-seven patients received regional pancreaticoduodenectomy (RP), 16 partial resection of the superior mesenteric vein-portal vein (SMV-PV) or superior mesenteric artery (SMA) and reconstruction, 1 anhydrous alcohol injection in the celiac nerve plexus, regional chemotherapy via a chemotherapy pump, and liver biopsy, and 5 no operation.
  • CONCLUSIONS: Pancreas uncinate process carcinoma invading the adjacent SMV/SMA-PV causes difficulty in early diagnosis and poor prognosis, which are related to its location, not tumor's aggressive nature.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / surgery. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pancreatectomy / methods. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14627529.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Beck A, Jonas J, Frenzel H, Bähr R: [Gastrointestinal autonomic nerve tumor]. Zentralbl Chir; 2001 Sep;126(9):702-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal autonomic nerve tumor].
  • Gastrointestinal autonomic nerve tumors (GAN-tumor) are rare malignant neurogenic stromal tumors of the intestinal tract.
  • The origin is suspected in the autonomic nerve plexus Meissner or Auerbach with the interstitial cells of Cajal as precursors.
  • We report on a 53-year-old patient with a clinical apparent and radiological 5 cm measuring tumor of the jejunum, which was resected and immunohistochemically verified as GAN-tumor.
  • Several trials of adjuvant chemotherapy (adriamycine/ifosamide, taxotere, gemcitabine/xyloda) were ineffective.
  • Since the first description of the GAN-tumor in 1984 87 patients were reported in the literature.
  • No recurrences or metastasis were seen in tumors with a seize less than 5 cm.
  • A tumor seize of more than 10 cm is associated with recurrences in 64% of the cases within 2 years.
  • Since there is no option for medical treatment, surgical resection is the treatment of choice and has to be considered also in the case of recurrence.
  • [MeSH-major] Autonomic Nervous System Diseases / surgery. Ileal Neoplasms / surgery. Ileum / innervation. Jejunal Neoplasms / surgery. Jejunum / innervation. Neoplasm Recurrence, Local / surgery. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Autonomic Nervous System / pathology. Combined Modality Therapy. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Autonomic Nervous System Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11699287.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Yan BM, Myers RP: Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am J Gastroenterol; 2007 Feb;102(2):430-8
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer.
  • The aim of this systematic review was to examine the efficacy and safety of neurolytic celiac plexus blockade (NCPB) compared with standard treatment in randomized controlled trials (RCTs) involving patients with unresectable pancreatic cancer.
  • METHODS: An electronic search was completed (1966 through August, 2005) for RCTs comparing NCPB versus control (standard treatment and/or sham NCPB) in patients with unresectable pancreatic cancer.
  • CONCLUSIONS: In patients with unresectable pancreatic cancer, NCPB is associated with improved pain control, and reduced narcotic usage and constipation compared with standard treatment, albeit with minimal clinical significance.
  • [MeSH-major] Abdominal Pain / drug therapy. Autonomic Nerve Block / methods. Celiac Plexus / drug effects. Palliative Care / methods. Pancreatic Neoplasms / complications
  • [MeSH-minor] Humans. Neoplasm Staging. Pain Measurement. Severity of Illness Index. Treatment Outcome


6. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H, Sueda T: Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma. J Gastrointest Surg; 2008 Mar;12(3):534-41
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma.
  • Pancreatic carcinoma is one of the most aggressive types of gastrointestinal malignancy, and its prognosis remains extremely dismal.
  • Overall 1-, 2-, and 5-year survival rates were 59, 28, and 7%, respectively (median survival time, 12.1 months).
  • Univariate analysis revealed that postoperative adjuvant chemotherapy, portal vein invasion, lymph node metastasis, extrapancreatic nerve plexus invasion, surgical margin status, UICC pT factor, and UICC stage were significantly associated with long-term survival (P<0.01).
  • Furthermore, use of postoperative adjuvant chemotherapy and absence of extrapancreatic nerve plexus invasion were found to be significant independent predictors of a favorable prognosis using a Cox proportional hazard regression model (P<0.05).
  • These results suggest that postoperative adjuvant chemotherapy may improve survival after surgical resection for pancreatic carcinoma and that extrapancreatic nerve plexus invasion indicates a poor prognosis for long-term survival.
  • [MeSH-major] Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Female. Fluorouracil / therapeutic use. Humans. Injections, Intra-Arterial. Male. Neoplasm Invasiveness. Postoperative Period. Proportional Hazards Models. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2003 Mar;27(3):324-9 [12607060.001]
  • [Cites] J Am Coll Surg. 1996 Aug;183(2):164-84 [8696550.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jan;385(1):14-20 [10664114.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Ann Surg Oncol. 2004 Jul;11(7):644-9 [15197014.001]
  • [Cites] Surgery. 2006 Sep;140(3):448-53 [16934608.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] Dig Surg. 2000;17(1):29-35 [10720829.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):568-74 [16465578.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Am J Surg. 2005 Mar;189(3):278-82 [15792750.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):36-40 [10861607.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Surgery. 1995 Jun;117(6):616-23 [7778025.001]
  • [Cites] Surgery. 2005 Oct;138(4):618-28; discussion 628-30 [16269290.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):549-58 [14962722.001]
  • [Cites] Pancreas. 2006 Jan;32(1):37-43 [16340742.001]
  • [Cites] Ann Surg. 1999 May;229(5):613-22; discussion 622-4 [10235519.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] Jpn J Clin Oncol. 2006 Mar;36(3):159-65 [16490736.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):447-54 [16855842.001]
  • [Cites] Oncology. 2005;68(2-3):171-8 [16006754.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] Surgery. 2005 Nov;138(5):962-3 [16291404.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] J Surg Oncol. 1997 Jul;65(3):164-70 [9236924.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):150-8 [16418882.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):21-3 [15597096.001]
  • [Cites] Pancreas. 1996 May;12(4):357-61 [8740402.001]
  • [Cites] Eur J Cancer. 1993;29A(5):698-703 [8471327.001]
  • [Cites] Pancreas. 2005 Jul;31(1):69-73 [15968250.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):595-610 [11459274.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):930-5 [1735083.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1575-9 [16721372.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Pancreas. 2003 Apr;26(3):243-9 [12657950.001]
  • [Cites] Surg Endosc. 2006 Apr;20 Suppl 2:S446-9 [16557419.001]
  • [Cites] Surgery. 2006 Mar;139(3):288-95 [16546491.001]
  • (PMID = 18026816.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Meola S, Olivieri M, Mirabile C, Mastrandrea P: Anesthetic management for right upper extremity amputation due to recidivous cutaneous carcinoma and acute postoperative pain control in patients affected by epidermolysis bullosa. Minerva Anestesiol; 2010 Feb;76(2):144-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, the intraoperative brachial plexus nerve block before amputation followed by positioning of an epidural catheter to deliver continuous infusion of local anesthetics close to the cut nerves during surgery obtained a very good level of acute postoperative pain control.
  • [MeSH-major] Amputation / methods. Anesthesia. Epidermolysis Bullosa / complications. Pain, Postoperative / drug therapy. Skin Neoplasms / complications. Skin Neoplasms / surgery. Upper Extremity / surgery
  • [MeSH-minor] Anesthesia, Epidural. Anesthetics, Local / therapeutic use. Brachial Plexus / physiology. Humans. Male. Monitoring, Intraoperative. Neoplasm Recurrence, Local. Young Adult

  • Genetic Alliance. consumer health - Epidermolysis Bullosa.
  • MedlinePlus Health Information. consumer health - Anesthesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150856.001).
  • [ISSN] 1827-1596
  • [Journal-full-title] Minerva anestesiologica
  • [ISO-abbreviation] Minerva Anestesiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anesthetics, Local
  •  go-up   go-down


8. Komuro T, Okamoto S: Pure intracerebral mass lesion of adult T-cell leukemia/lymphoma--case report. Neurol Med Chir (Tokyo); 2010;50(6):492-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroimaging revealed a solitary enhanced mass lesion in the right occipital lobe adjacent to the choroid plexus with prominent perifocal edema.
  • She underwent radiation therapy and chemotherapy after local recurrence and metastasis to an optic nerve.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Occipital Lobe / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20587977.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Miki M, Masaki Y, Nakamura T, Iwao H, Nakajima A, Sakai T, Sawaki T, Kawanami T, Kaito M, Kurose N, Fujita Y, Tanaka M, Fukushima T, Hirose Y, Umehara H: [Primary neurolymphomatosis of the cervical nerve root]. Rinsho Ketsueki; 2010 Jul;51(7):564-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary neurolymphomatosis of the cervical nerve root].
  • On (18)FDG-PET, abnormal accumulation was noted on both sides of the brachial plexus at the cervical spinal cord.
  • A diagnosis of primary peripheral nerve neurolymphomatosis was made based on biopsy of the third cervical nerve.
  • Following R-CHOP therapy, the abnormal accumulation of (18)FDG-PET scan disappeared.
  • However, disturbance of consciousness occurred 6 months later and recurrence as multiple brain tumors was detected.
  • Although salvage chemotherapy was performed, the patient died of overwhelming sepsis.
  • Primary peripheral nerve neurolymphomatosis is extremely rare.
  • Early distinct diagnosis using (18)FDG-PET and combination chemotherapy of rituximab and high dose methotrexate may improve the outcome for such patients.
  • [MeSH-major] Cervical Vertebrae. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Nervous System Neoplasms / therapy. Spinal Nerve Roots
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. Humans. Methotrexate / administration & dosage. Neoplasm Recurrence, Local. Neurosurgical Procedures. Positron-Emission Tomography. Prednisolone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20693778.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate; VAP-cyclo protocol
  •  go-up   go-down


10. Shirouzu K, Ogata Y, Araki Y: Oncologic and functional results of total mesorectal excision and autonomic nerve-preserving operation for advanced lower rectal cancer. Dis Colon Rectum; 2004 Sep;47(9):1442-7
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic and functional results of total mesorectal excision and autonomic nerve-preserving operation for advanced lower rectal cancer.
  • PURPOSE: Total mesorectal excision contains two different procedures: autonomic nerve preservation, and autonomic nerve sacrifice.
  • It is unclear whether autonomic nerve preservation is suitable curative procedure.
  • We clarify the significance of autonomic nerve preservation for an advanced lower rectal cancer.
  • Between 1975 and 1984, all patients routinely received total mesorectal excision without autonomic nerve preservation (TME-P(-) group).
  • Since 1985, total mesorectal excision with autonomic nerve preservation has been performed in 81 percent of patients (TME-P(+) group).
  • The remaining patients received TME-P(-) because of suspicious invasion to autonomic nerve plexus.
  • CONCLUSIONS: Autonomic nerve preservation is oncologically and functionally excellent and suitable for almost all patients with advanced lower rectal cancer.
  • Intensive chemotherapy is needed for patients whose autonomic nerves were killed in suspicion of nerve invasion.
  • [MeSH-major] Autonomic Nervous System / injuries. Lymph Node Excision. Neoplasm Recurrence, Local. Postoperative Complications / prevention & control. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Sexual Dysfunction, Physiological / etiology. Survival Analysis. Treatment Outcome. Urination Disorders / etiology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15486739.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Kulke MH: Metastatic pancreatic cancer. Curr Treat Options Oncol; 2002 Dec;3(6):449-57
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the past, patients with metastatic pancreatic cancer have had few treatment options.
  • However, recently, several effective palliative therapies and procedures have become available.
  • The systemic administration of gemcitabine has been shown to result in clinical benefit and in a prolongation of median survival, and is now established as the standard first-line treatment for patients with metastatic pancreatic cancer.
  • Clinical trials are exploring whether the use of gemcitabine-based chemotherapy combinations will result in further benefit.
  • Several novel chemotherapeutic and biologic agents appear promising, and are likely to play a role in the treatment of patients with pancreatic cancer in the future.
  • Palliative procedures, such as biliary or duodenal stenting and celiac plexus blockade, should be considered in conjunction with systemic therapy in patients with specific complications from pancreatic cancer.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Palliative Care. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Autonomic Nerve Block. Celiac Plexus. Cholestasis / etiology. Cholestasis / therapy. Clinical Trials as Topic. Combined Modality Therapy. Digestive System Diseases / surgery. Fluorouracil / therapeutic use. Gastric Outlet Obstruction / etiology. Gastric Outlet Obstruction / therapy. Humans. Neoplasm Metastasis. Neuralgia / etiology. Neuralgia / therapy. Risk Factors. Stents


12. Wasner G, Hilpert F, Schattschneider J, Binder A, Pfisterer J, Baron R: Docetaxel-induced nail changes--a neurogenic mechanism: a case report. J Neurooncol; 2002 Jun;58(2):167-74
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Docetaxel is a new taxoid widely used in chemotherapy for advanced breast cancer and other solid malignancies.
  • We report a patient with a complete peripheral palsy of the right arm due to advanced breast cancer with diffuse tumor infiltration of the brachial plexus.
  • Treatment with docetaxel led to onycholysis at all extremities except the paretic hand.
  • Sensory and motoric innervation measured by nerve conduction studies showed a complete loss of large nerve fiber function of the right arm.
  • [MeSH-major] Arm. Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Nail Diseases / chemically induced. Paclitaxel / adverse effects. Paclitaxel / analogs & derivatives. Paralysis / etiology. Taxoids
  • [MeSH-minor] Afferent Pathways / physiopathology. Brachial Plexus / pathology. Efferent Pathways / physiopathology. Female. Humans. Middle Aged. Motor Neurons / physiology. Neoplasm Invasiveness. Neural Conduction. Neurologic Examination. Neurons, Afferent / physiology. Parasympathetic Nervous System / physiopathology. Sensory Thresholds. Skin / innervation. Sympathetic Nervous System / physiopathology. Vibration

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Paralysis.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Physiol. 1980 Sep;306:537-52 [7463376.001]
  • [Cites] Science. 1990 Apr 20;248(4953):370-2 [1970196.001]
  • [Cites] Semin Oncol. 1995 Dec;22(6 Suppl 13):17-21 [8604448.001]
  • [Cites] Lancet. 2000 Aug 5;356(9228):507-8 [10981914.001]
  • [Cites] Mayo Clin Proc. 1983 Sep;58(9):583-92 [6310277.001]
  • [Cites] Pain. 1996 Oct;67(2-3):317-26 [8951925.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1672-8 [8622087.001]
  • [Cites] Dermatology. 1999;198(3):288-90 [10393455.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3149-55 [9294478.001]
  • [Cites] J Neurol. 2000 Apr;247(4):267-72 [10836618.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):910 [11289346.001]
  • [Cites] Diabet Med. 1992 Mar;9(2):166-75 [1563252.001]
  • [Cites] J Leukoc Biol. 1992 Jul;52(1):119-21 [1353517.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):527-32 [7918124.001]
  • [Cites] Neuroscience. 1995 Mar;65(1):283-91 [7753402.001]
  • [Cites] Neuroscience. 1997 Nov;81(1):255-62 [9300418.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1976 Nov;39(11):1071-5 [188989.001]
  • [Cites] Cancer. 2000 May 15;88(10):2367-71 [10820360.001]
  • [Cites] Ann Oncol. 1998 Feb;9(2):230-1 [9553674.001]
  • [Cites] Brain. 1991 Aug;114 ( Pt 4):1819-26 [1884180.001]
  • [Cites] Ann Pharmacother. 1999 May;33(5):584-6 [10369623.001]
  • [Cites] J Auton Nerv Syst. 1996 Sep 12;60(3):147-53 [8912264.001]
  • [Cites] Brain. 1993 Dec;116 ( Pt 6):1477-96 [8293282.001]
  • [Cites] Bibl Anat. 1965;7:314-24 [5860752.001]
  • [Cites] Muscle Nerve. 1993 Jul;16(7):757-68 [8505932.001]
  • [Cites] Muscle Nerve. 1992 Apr;15(4):507-12 [1565120.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):610-1 [8103352.001]
  • [Cites] J Am Acad Dermatol. 1984 Feb;10(2 Pt 1):250-8 [6371069.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1991 Nov;54(11):965-71 [1800668.001]
  • [Cites] J Neurosci. 1997 May 1;17(9):3234-8 [9157197.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1992;121:49-146 [1485073.001]
  • [Cites] Lancet. 2000 Apr 1;355(9210):1176-8 [10791395.001]
  • [Cites] J Physiol. 1992 Mar;448:749-64 [1593488.001]
  • [Cites] Arch Dermatol. 1998 Sep;134(9):1167-8 [9762045.001]
  • (PMID = 12164689.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Kurahara H, Shinchi H, Maemura K, Mataki Y, Aoki M, Sakoda M, Ueno S, Natsugoe S, Takao S: [A case of curatively resected locally advanced pancreatic cancer after chemoradiation therapy]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1983-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of curatively resected locally advanced pancreatic cancer after chemoradiation therapy].
  • A 68-year-old man admitted for pancreatic tumor detected by US was found by computed tomography(CT)to have locally advanced pancreatic cancer invading the portal vein and neural plexus of the superior mesenteric artery without distant metastasis.
  • We conducted preoperative chemoradiation therapy containing S-1 and hyperfractionated accelerated radiation therapy (50 Gy).
  • Reevaluation of CT after chemoradiation therapy showed that the primary tumor reduced 52% without distant metastasis.
  • Extensive fibrosis with a small amount of cancer cells was observed in the marginal area of the tumor.
  • Extrapancreatic nerve plexus invasion and lymph node metastasis were not observed.
  • The postoperative course was uneventful, and adjuvant chemotherapy (S-1) was started.
  • [MeSH-major] Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Humans. Male. Neoplasm Staging. Oxonic Acid / therapeutic use. Tegafur / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948269.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


14. Snady H: Interventional endoscopy, neoadjuvant therapy and the gastroenterologist. Hematol Oncol Clin North Am; 2002 Feb;16(1):53-79
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventional endoscopy, neoadjuvant therapy and the gastroenterologist.
  • With current treatment, survival of greater than 1 year should be anticipated for many patients with pancreatic cancer.
  • Relief of biliary obstruction allows improvement in liver function and more time to evaluate tumor stage accurately to determine initial treatment (see Fig. 1).
  • A cost-effective algorithm to determine accurate stage and treatment can start with the size of the mass on initial imaging studies.
  • EUS-guided FNA represents a significant improvement over CT scan-guided FNA to make a tissue diagnosis.
  • Tumors reliably staged as unresectable by nonoperative imaging methods including EUS are treated with chemotherapy with or without concurrent radiotherapy because median survival of these patients is 2 years in some series.
  • Tumors can be resected after neoadjuvant chemoradiotherapy.
  • For chronic pain or gastric outlet obstruction not responding or treatable by chemoradiotherapy, endoscopically guided celiac plexus nerve block and stenting improve the quality of life for patients with pancreatic cancer.
  • Rather than reliance on any single standard, clinical judgment and communication among the team are paramount to providing optimal care for patients with a pancreatic neoplasm.
  • [MeSH-major] Adenocarcinoma / therapy. Endoscopy. Endoscopy, Gastrointestinal. Endosonography. Neoadjuvant Therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Ampulla of Vater / surgery. Antineoplastic Agents / therapeutic use. Autonomic Nerve Block / methods. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / therapy. Chemotherapy, Adjuvant. Cholangiopancreatography, Endoscopic Retrograde. Cholestasis / etiology. Cholestasis / therapy. Combined Modality Therapy. Common Bile Duct Neoplasms / surgery. Diagnostic Imaging / methods. Gastric Outlet Obstruction / surgery. Humans. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasm Staging / methods. Pain Management. Palliative Care. Pancreatic Cyst / therapy. Prognosis. Radiotherapy, Adjuvant. Stents

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12063829.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 115
  •  go-up   go-down


15. Lee JL, Kang YK, Kim TW, Chang HM, Lee GW, Ryu MH, Kim E, Oh SJ, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Lee JS, Kim WK, Kim SH: Leptomeningeal carcinomatosis in gastric cancer. J Neurooncol; 2004 Jan;66(1-2):167-74
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the exception of 1 patient, the primary gastric cancer was Borrmann type III or IV, and 88% had poorly differentiated or signet-ring cell histology.
  • The distribution of extraneural metastasis suggested that Batson's venous plexus might be the predominant route to the subarachnoid space.
  • Eighty percent of the patients had multiple neuraxis syndrome, and the combination of brain plus cranial nerve syndrome was the most common manifestation.
  • Computed tomography (CT) findings were abnormal in a minor proportion of the patients, while magnetic resonance imaging (MRI) revealed abnormality in 67% of the patients, which could help the diagnosis.
  • By univariate analysis, good performance status, intrathecal chemotherapy, and low CSF LDH concentration favored survival.
  • Multivariate analysis revealed that the administration of CSF chemotherapy was the independent prognostic factor for survival.
  • [MeSH-major] Carcinoma / pathology. Meningeal Neoplasms / pathology. Neoplasms, Second Primary / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cranial Nerve Neoplasms / pathology. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Nervous System Diseases / etiology. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurol (Napoli). 1976 May-Jun;31(3):262-9 [1015368.001]
  • [Cites] Arch Neurol. 1988 Jul;45(7):741-4 [3390029.001]
  • [Cites] Cancer. 1986 Dec 15;58(12 ):2656-61 [3779615.001]
  • [Cites] Pathol Res Pract. 1991 Mar;187(2-3):341-5; discussion 345-7 [2068018.001]
  • [Cites] J Neurooncol. 1998 Jun-Jul;38(2-3):103-10 [9696359.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):771-6 [10622506.001]
  • [Cites] Neurol Med Chir (Tokyo). 1979 Jan;19(1):39-44 [84354.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Arch Neurol. 1998 Apr;55(4):506-12 [9561978.001]
  • [Cites] Arch Neurol. 1996 Jul;53(7):626-32 [8929170.001]
  • [Cites] Gastroenterol Clin Biol. 2001 Apr;25(4):422-4 [11449130.001]
  • [Cites] Arch Neurol. 1974 Feb;30(2):122-37 [4405841.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1462-6 [1515997.001]
  • [Cites] Clin Neurol Neurosurg. 1992;94(3):235-40 [1327614.001]
  • [Cites] Arch Neurol. 1994 May;51(5):457-61 [8179494.001]
  • [Cites] Cancer Treat Rev. 1999 Apr;25(2):103-19 [10395835.001]
  • [Cites] Cancer. 1951 May;4(3):610-8 [14839615.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):225-9 [2086737.001]
  • [Cites] J Neurooncol. 1997 Oct;35(1):55-64 [9266441.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1685-95 [2001559.001]
  • [Cites] Ann Neurol. 1995 Jul;38(1):51-7 [7611725.001]
  • [Cites] J Neurooncol. 1999 May;43(1):59-62 [10448872.001]
  • [Cites] Surgery. 1990 Feb;107(2):140-8 [1689080.001]
  • [Cites] Surg Today. 2000;30(6):485-90 [10883456.001]
  • [Cites] Neurology. 1955 Oct;5(10):706-22 [13265982.001]
  • [Cites] South Med J. 1979 Aug;72(8):930-2 [472815.001]
  • [Cites] J Neurooncol. 1998 Jun-Jul;38(2-3):245-52 [9696379.001]
  • (PMID = 15015782.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Krarup C, Crone C: Neurophysiological studies in malignant disease with particular reference to involvement of peripheral nerves. J Neurol; 2002 Jun;249(6):651-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurological and neuromuscular disorders are frequent complications in patients with neoplasms and may involve the neuromuscular system, including motor and sensory nerve cell bodies, axons, myelin, neuromuscular transmission and muscle alone or in combination.
  • Electrophysiological studies are of value in delineating the type, degree and extent of involvement, and may be of assistance in pointing towards the underlying cause: paraneoplastic factors, treatment with chemotherapy or radiation or metastatic infiltration.
  • Even in cases where such studies are obtained, a final diagnosis may only be ascertained during follow up, since the neuromuscular disorders frequently occur before the neoplasm is detected.
  • [MeSH-major] Central Nervous System Diseases / etiology. Meningeal Neoplasms / secondary. Neoplasm Metastasis / physiopathology. Neoplasms / complications. Paraneoplastic Polyneuropathy / physiopathology
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brachial Plexus Neuropathies / etiology. Brachial Plexus Neuropathies / pathology. Brachial Plexus Neuropathies / physiopathology. Humans. Lumbosacral Plexus / drug effects. Lumbosacral Plexus / physiopathology. Lumbosacral Plexus / radiation effects. Neural Conduction / physiology. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12111295.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 113
  •  go-up   go-down


17. Papanastassiou I, Ioannou M, Magoulas D, Lalos S, Athanassiou AE, Ziras N, Thanopoulou E, Demertzis N: Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma. J BUON; 2009 Jul-Sep;14(3):507-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma.
  • A 26 year-old male was referred to our unit because of a stage III soft tissue sarcoma in the shoulder girdle-axillary area and reduced forearm-distal arm strength.
  • Imaging studies revealed that the tumor encompassed the axillary artery and brachial plexus.
  • The patient received adjuvant chemotherapy (ifosfamide/mesna, adriamycin, and dacarbazine/MAID) and finally radiation therapy (RT; 6500 cGy total dose).
  • In stage III soft tissue sarcomas, especially in proximity with major nerve/arterial bundles, a multimodality approach is mandatory; chemoembolization is very effective in shrinking the tumor and defining its margins so as to make feasible a LSS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Embolization, Therapeutic. Limb Salvage. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810146.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


18. Matsukawa H, Shiozaki S, Takakura N, Aoki H, Fujiwara Y, Ohno S, Ojima Y, Harano M, Nishizaki M, Choda Y, Ninomiya M: [A 6-year survival case of locally advanced unresectable pancreatic tail cancer treated with chemo-radiation therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2355-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A 6-year survival case of locally advanced unresectable pancreatic tail cancer treated with chemo-radiation therapy].
  • We report a case of locally advanced unresectable pancreatic tail cancer patient who survived over 6 years by chemo-radiation therapy (CRT).
  • A 61-year-old male was pointed out by CT to have pancreatic tail cancer of 5.6 cm in diameter that invaded to the stomach, left kidney and adrenal gland, nerve plexus of celiac and superior mesenteric artery, was diagnosed as locally advanced unresectable pancreatic tail cancer.
  • After 4 years and 5 months, paraaortic lymph node metastasis was enlarged, so chemotherapy was changed to combination of GEM + S-1.
  • In the case of pancreatic cancer that CRT is effective to the remission of primary lesion, CRT is potentially useful to perform for the control of metastatic lesion or palliative therapy.
  • [MeSH-major] Pancreatic Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Drug Combinations. Fatal Outcome. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Oxonic Acid / therapeutic use. Palliative Care. Tegafur / therapeutic use

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224571.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


19. von Falck C, Rodt T, Joerdens S, Waldeck S, Kiesel H, Knapp WH, Galanski M: F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography for the detection of radicular and peripheral neurolymphomatosis: correlation with magnetic resonance imaging and ultrasound. Clin Nucl Med; 2009 Aug;34(8):493-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography for the detection of radicular and peripheral neurolymphomatosis: correlation with magnetic resonance imaging and ultrasound.
  • As blind nerve biopsy is invasive and may be false negative, surrogate criteria for the diagnosis of neurolymphomatosis have been proposed based on magnetic resonance imaging/computed tomography findings.
  • Recently, a few reports have been published that discuss a possible advantage of F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (F-18 FDG PET/CT) in these patients.We report the case of a 41-year-old man who presented with progressive tetraparesis and dysaesthesia, in which F-18 FDG PET/CT aided to the diagnosis of neurolymphomatosis due to a large B-cell lymphoma.
  • The patient received chemotherapy (R-CHOP) and the neurologic symptoms were clearly regressive.
  • Three months after the end of systemic chemotherapy the patient presented again with progressive neurologic symptoms.
  • Additional ultrasound and magnetic resonance imaging examinations were performed and confirmed infiltration of the left brachial plexus, the right femoral, and the right sciatic nerve.We present this case to support the hypothesis that F-18 FDG PET/CT is a valuable imaging modality in patients with suspected neurolymphomatosis.
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Positron-Emission Tomography. Recurrence. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617723.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Geenen JE: Benign pancreatic duct strictures: medical and endoscopic therapy. Can J Gastroenterol; 2000 Feb;14(2):127-9
Hazardous Substances Data Bank. PANCREATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign pancreatic duct strictures: medical and endoscopic therapy.
  • Pancreatic duct strictures usually reflect underlying pancreatic disease and are likely caused by one or more of the following: acute or chronic pancreatitis, benign or malignant pancreatic neoplasm, pseudocyst and trauma.
  • The characteristics of pancreatic strictures are identified, and medical and endoscopic therapy options are reviewed.
  • [MeSH-major] Analgesics / therapeutic use. Autonomic Nerve Block. Diet, Fat-Restricted. Endoscopy. Pancreatic Diseases / therapy. Pancreatic Ducts. Pancreatin / therapeutic use
  • [MeSH-minor] Celiac Plexus. Constriction, Pathologic / etiology. Constriction, Pathologic / therapy. Decision Making. Drug Therapy, Combination. Gastrointestinal Agents / therapeutic use. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10694285.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] CANADA
  • [Chemical-registry-number] 0 / Analgesics; 0 / Gastrointestinal Agents; 8049-47-6 / Pancreatin
  • [Number-of-references] 6
  •  go-up   go-down


21. Ye C, Xi P, Hu X: [Uncinate process carcinoma of the pancreas: clinical features and diagnosis and treatment]. Zhonghua Wai Ke Za Zhi; 2002 Oct;40(10):766-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uncinate process carcinoma of the pancreas: clinical features and diagnosis and treatment].
  • OBJECTIVE: To summarize the clinical features and diagnosis and treatment of uncinate process carcinoma of the pancreas.
  • Alcohol injection was made in the nerve plexus of the trunks of both celic axes and the superior mesenteric artery and regional chemotherapy via chemotherapy pump and liver biopsy in one case.
  • [MeSH-major] Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12487881.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Okabayashi T, Nishimori I, Nishioka A, Yamashita K, Sugimoto T, Dabanaka K, Maeda H, Kohsaki T, Ogawa Y, Kobayashi M, Onishi S, Hanazaki K: Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas. Oncol Rep; 2008 Sep;20(3):651-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
  • The treatment of pancreatic carcinoma remains one of the most formidable challenges in oncology.
  • Curative resection, currently the only available treatment option, provides no significant impact on long-term survival.
  • The recent development of multimodal treatment options for pancreatic cancer has provided clinical benefits and improved patient survival.
  • In this study, we retrospectively evaluated our experiences with multimodal therapy, including radiotherapy and chemotherapy with gemcitabine, for the treatment of resectable pancreatic cancer.
  • The clinical and pathological factors and multimodal treatment for pancreatic carcinoma that influenced patient survival were analyzed.
  • The overall 4-year survival rate of patients subjected to adjuvant chemotherapy with gemcitabine after curative resection for ordinary pancreatic carcinoma is 39.1%.
  • Adjuvant chemotherapy with gemcitabine provided a significantly better prognosis for patients following curative surgical resection than curative surgical resection alone (P=0.035).
  • Postoperative local recurrence around the nerve plexus of celiac and superior mesenteric arteries was better controlled in patients who underwent radiotherapy than those who did not.
  • Adjuvant chemotherapy with gemcitabine after curative resection provides a significant survival benefit for patients with pancreatic carcinoma.
  • Our results suggest that the postoperative recurrence of ordinary pancreatic carcinoma will be reduced by multimodal treatment using radiotherapy and adjuvant chemotherapy with gemcitabine.
  • [MeSH-major] Adenocarcinoma / surgery. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy / trends. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Prognosis. Radiotherapy Dosage. Retrospective Studies. Ribonucleotide Reductases / antagonists & inhibitors. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695919.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases
  •  go-up   go-down


23. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD: Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve; 2001 Aug;24(8):1050-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-seven men with metastatic androgen-independent prostate cancer in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment.
  • NCS included recording of sensory nerve action potentials (SNAPs) from median, radial, ulnar, and sural nerves.
  • SNAP amplitudes for each nerve were expressed as the percentage of its baseline, and the mean of the four was termed the SNAP index.
  • Thalidomide was discontinued in 55 patients for lack of therapeutic response.
  • Six patients developed neuropathy.
  • The SNAP index can be used to monitor peripheral neuropathy, but not for early detection.
  • [MeSH-major] Peripheral Nervous System Diseases / chemically induced. Peripheral Nervous System Diseases / diagnosis. Prostatic Neoplasms / drug therapy. Thalidomide / adverse effects
  • [MeSH-minor] Action Potentials / drug effects. Age Factors. Aged. Aged, 80 and over. Brachial Plexus / drug effects. Brachial Plexus / physiopathology. Cohort Studies. Dose-Response Relationship, Drug. Electrodiagnosis. Electromyography. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neural Conduction / drug effects. Neurons, Afferent / drug effects. Prospective Studies. Risk Factors. Sural Nerve / drug effects. Sural Nerve / physiopathology


24. Boes M, Pels H, Klockgether T, Koch A, Schlegel U: High-grade B-cell NHL of the brachial plexus followed by infiltration of the spinal cord. J Neurol; 2008 Jan;255(1):135-7
MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade B-cell NHL of the brachial plexus followed by infiltration of the spinal cord.
  • [MeSH-major] Brachial Plexus Neuropathies / etiology. Brachial Plexus Neuropathies / pathology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / pathology. Neoplasm Invasiveness / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Arm / innervation. Arm / physiopathology. Brachial Plexus / pathology. Brachial Plexus / physiopathology. Cavernous Sinus Thrombosis / etiology. Cavernous Sinus Thrombosis / pathology. Cavernous Sinus Thrombosis / physiopathology. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / pathology. Cranial Nerve Diseases / physiopathology. Fatal Outcome. Female. Ganglia, Spinal / pathology. Ganglia, Spinal / physiopathology. Humans. Magnetic Resonance Imaging. Middle Aged. Muscle Weakness / etiology. Muscle Weakness / physiopathology. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Spinal Cord / pathology. Spinal Cord / physiopathology. Spinal Nerve Roots / pathology. Spinal Nerve Roots / physiopathology. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1257-65 [10976700.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):618-21; discussion 621-2 [9055305.001]
  • [Cites] J Neurosurg. 2000 Jan;92(1):165-9 [10616097.001]
  • [Cites] Auris Nasus Larynx. 1999 Jul;26(3):337-42 [10419043.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4471-3 [14597745.001]
  • (PMID = 17994311.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement